Healthcare Industry News: IMMray
News Release - October 19, 2022
Immunovia Announces Executive Management Team Changes to Accelerate Execution of Strategic PrioritiesLUND, Sweden, Oct. 19, 2022 -- (Healthcare Sales & Marketing Network) -- Immunovia AB (Nasdaq Stockholm: IMMNOV) today announced changes to its executive management team to accelerate the execution of its strategic priorities.
The leaner organization structure will in particular focus on the commercial roll-out of the IMMray PanCan-d test in the U.S. and the strategic R&D partnership with Proteomedix announced earlier this week.
"We have been taking important steps and made significant progress in executing on the Company's strategic priorities which I set out in February. A leaner executive management team will ensure that the Immunovia team remains focused on executing our strategic plan and delivering commercial growth," says Philipp Mathieu – CEO,Immunovia.
For more information, please contact:
CEO and President
Karin Almqvist Liwendahl
Chief Financial Officer
+46 709 11 56 08
Immunovia AB is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer.
Our first product, IMMray™ PanCan-d is the only blood test currently available for early detection of pancreatic cancer. The test has unmatched clinical performance. Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see: www.immunoviainc.com.
Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups globally to make this test available to all high-risk pancreatic cancer groups.
The USA, the first market in which IMMray™ PanCan-d is commercially available, is the world's largest market for the detection of pancreatic cancer with an estimated value of more than USD 4 billion annually.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit https://immunovia.com/
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.